Data as of 4:02pm ET
| -0.01 / -0.30%|
The 3 analysts offering 12-month price forecasts for Protalix Biotherapeutics Inc have a median target of 6.00, with a high estimate of 8.00 and a low estimate of 4.25. The median estimate represents a +82.93% increase from the last price of 3.28.
The current consensus among 4 polled investment analysts is to Buy stock in Protalix Biotherapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.